Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04693195 · ClinicalTrials.gov registry record · Phase 2

A Multiple-Dose Study of BLU-5937 in Chronic Pruritus Associated With Atopic Dermatitis

A Phase 2 study of Atopic Dermatitis and Chronic Pruritus, sponsored by Bellus Health Inc. - a GSK company.

Completed
Registry status
Phase 2
Development phase
142
Enrollment target
20
Study locations

NCT04693195 is a Phase 2 study of Atopic Dermatitis and Chronic Pruritus that has completed, run by Bellus Health Inc. - a GSK company. The registered enrollment target is 142 participants, below the 608-participant average among 150 other Atopic Dermatitis trials with a reported enrollment target (77% lower). The trial reports 20 study locations across 10 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04693195, a Phase 2 study of Atopic Dermatitis and Chronic Pruritus, has completed, sponsored by Bellus Health Inc. - a GSK company.

COMPLETED
Registry status
Phase 2
Development phase
142 participants
Enrollment target
20
Study locations

Study Summary

This is a multicenter, randomized, double-blind, placebo-controlled, parallel design study of BLU-5937 for the treatment of chronic pruritus in adult subjects with atopic dermatitis (AD).

Conditions Studied

Atopic Dermatitis Chronic Pruritus

Interventions

  • DRUG Placebo
  • DRUG BLU-5937

Study Locations (20)

Florida

  • Bellus Health Investigational Site #15 - Hialeah
  • Bellus Health Investigational Site #32 - Margate
  • Bellus Health Investigational Site #16 - Miami
  • Bellus Health Investigational Site #19 - Miami
  • Bellus Health Investigational Site #17 - Sweetwater

California

  • Bellus Health Investigational Site #23 - Beverly Hills
  • Bellus Health Investigational Site #33 - Encinitas
  • Bellus Health Investigational Site #27 - Fountain Valley
  • Bellus Health Investigational Site #35 - San Diego

Louisiana

  • Bellus Health Investigational Site #38 - Baton Rouge
  • Bellus Health Investigational Site #45 - Covington
  • Bellus Health Investigational Site #18 - New Orleans

Arizona

  • Bellus Health Investigational Site #28 - Phoenix
  • Bellus Health Investigational Site #10 - Scottsdale

Georgia

  • Bellus Health Investigational Site #24 - Savannah

Kentucky

  • Bellus Health Investigational Site #13 - Owensboro

Minnesota

  • Bellus Health Investigational Site #36 - Minneapolis

New Hampshire

  • Bellus Health Investigational Site #22 - Portsmouth

Trial Details

FieldValue
Enrollment Target 142 participants
Start Date 2020-12-09
Est. Completion 2021-10-12
Phase Phase 2

Sponsor

Bellus Health Inc. - a GSK company

9 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT04693195

The ClinicalTrials.gov registry entry for NCT04693195 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 142 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 608-participant average among 150 other Atopic Dermatitis trials with a reported enrollment target (77% lower). The listed sponsor is Bellus Health Inc. - a GSK company, which has 9 total studies on file at ClinicalTrials.gov.

The record links to 2 conditions, with Atopic Dermatitis appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.

NCT04693195 reports 20 study locations spanning 10 distinct geographic areas - top geographies include Florida, California, Louisiana.

Frequently Asked Questions

What is clinical trial NCT04693195 about?

NCT04693195 is a clinical study titled "A Multiple-Dose Study of BLU-5937 in Chronic Pruritus Associated With Atopic Dermatitis". This is a multicenter, randomized, double-blind, placebo-controlled, parallel design study of BLU-5937 for the treatment of chronic pruritus in adult subjects with atopic dermatitis (AD).

What is the current status of trial NCT04693195?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 142 participants. The study started on 2020-12-09. Estimated completion is 2021-10-12.

What conditions does trial NCT04693195 study?

This clinical trial studies the following conditions: Atopic Dermatitis, Chronic Pruritus.

What interventions are being tested in trial NCT04693195?

The interventions under investigation include: Placebo (DRUG), BLU-5937 (DRUG).

Who is sponsoring clinical trial NCT04693195?

This trial is sponsored by Bellus Health Inc. - a GSK company, which has 9 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT04693195 being conducted?

This trial has 20 study locations across Arizona, California, Florida, Georgia, Kentucky. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Atopic Dermatitis

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Atopic Dermatitis

All registered trials for this condition

Chronic Pruritus

All registered trials for this condition

Arizona

All trials with a study site in Arizona

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.